Review
Cell Biology
Nicola Polverelli, Mirko Farina, Mariella D'Adda, Enrico Damiani, Luigi Grazioli, Alessandro Leoni, Michele Malagola, Simona Bernardi, Domenico Russo
Summary: Moving from indication to transplantation is a critical process in managing myelofibrosis patients. This review focuses on identifying suitable candidates for transplantation using disease-specific prognostic scores and evaluating their eligibility based on performance, comorbidity, and other combined tools. The review also discusses the importance of pre-transplant management in achieving successful engraftment and reducing non-relapse mortality and relapse incidence. Topics such as managing splenomegaly, constitutional symptoms, cytopenias, iron overload, and choosing the right donor and conditioning regimens are comprehensively explored. The aim of this review is to provide practical guidance for managing myelofibrosis patients who may undergo allo-HCT.
Review
Cell & Tissue Engineering
Zheng-Li Xu, Xiao-Jun Huang
Summary: Allogeneic hematopoietic stem cell transplantation is widely used in treating hematological diseases, with optimized grafts being crucial for improving outcomes. However, there is currently no uniform standard for optimized grafts in transplantation. Future research may focus on identifying the cellular elements responsible for the effects of allo-HSCT.
STEM CELLS TRANSLATIONAL MEDICINE
(2021)
Review
Immunology
Andrea Bacigalupo, Idanna Innocenti, Elena Rossi, Federica Sora, Eugenio Galli, Francesco Autore, Elisabetta Metafuni, Patrizia Chiusolo, Sabrina Giammarco, Luca Laurenti, Giulia Benintende, Simona Sica, Valerio De Stefano
Summary: This review provides an update on the current status of allogeneic HSCT for patients with myelofibrosis, covering indications, prognostic scoring systems, transplant outcome prediction, transplant platform choice, and complications.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Health Care Sciences & Services
Heather R. Wolfe, Mitchell E. Horwitz, Lindsay A. M. Rein
Summary: Primary myelofibrosis is a BCR-ABL1 negative myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells. Allogenic hematopoietic stem cell transplantation may provide a safe and effective curative option for a broader range of primary myelofibrosis patients in the future.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Nausheen Yaqoob, Neelum Mansoor, Hania Naveed, Saba Jamal
Summary: Extramedullary hematopoiesis is a pathophysiologic response where hematopoietic tissue proliferates outside the bone marrow medullary space, often associated with benign or malignant hematologic diseases. This case report describes a 61-year-old male with primary myelofibrosis presenting with extramedullary hematopoiesis in an inguinal lymph node, emphasizing the importance of integrated diagnostic approaches in challenging cases.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Qingyuan Wang, Na Xu, Yu Wang, Xi Zhang, Limin Liu, Huifen Zhou, Hong Wang, Xiang Zhang, Xiaowen Tang, Chengcheng Fu, Miao Miao, Depei Wu
Summary: The findings of the study indicate that allo-SCT combined with MSC transfusion may represent an effective treatment option for primary myelofibrosis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Christopher Cipkar, Srishti Kumar, Kednapa Thavorn, Natasha Kekre
Summary: This study developed a Markov cohort model to simulate the long-term disease trajectory of patients with primary myelofibrosis (PMF) and predict the optimal timing of transplantation based on the Dynamic International Prognostic Scoring System (DIPSS) risk. The results showed that transplantation benefited all patients with PMF in terms of life expectancy gained, with the timing varying based on the risk level. High-risk patients had the highest life expectancy gains from transplantation, while low-risk patients could delay transplantation for greater net gain in life expectancy.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Oncology
Juan Carlos Hernandez-Boluda, Arturo Pereira, Nicolaus Kroeger, Dietrich Beelen, Marie Robin, Martin Bornhaeuser, Emanuele Angelucci, Antonin Vitek, Igor Wolfgang Blau, Riitta Niittyvuopio, Juergen Finke, Jan J. Cornelissen, Jakob Passweg, Peter Dreger, Eefke Petersen, Lothar Kanz, Jaime Sanz, Tsila Zuckerman, Nienke Zinger, Simona Iacobelli, Patrick Hayden, Tomasz Czerw, Donal McLornan, Ibrahim Yakoub-Agha
Summary: This study aimed to evaluate survival determinants in myelofibrosis patients undergoing allo-HCT and describe factors predicting post-HCT complications. Factors associated with increased mortality included age, Karnofsky Performance Status, graft failure, aGVHD, and disease progression/relapse. Risk of aGVHD and relapse incidence varied with donor type and conditioning regimen, with GVHD having a complex impact on relapse and survival.
Article
Clinical Neurology
Shogo Shirota, Daisuke Katoh, Yoshimitsu Shimomura, Yukihiro Imai, Takayuki Ishikawa
Summary: This case report highlights the rare occurrence of extramedullary relapse of acute myeloid leukemia in the brachial plexus after allogeneic hematopoietic stem cell transplantation, emphasizing the importance of considering extramedullary relapse as a differential diagnosis in patients with leukemia presenting with paresthesia post-transplant.
Article
Oncology
Sarah Jungius, Franziska C. Adam, Kerstin Grosheintz, Michael Medinger, Andreas Buser, Jakob R. Passweg, Joerg P. Halter, Sara C. Meyer
Summary: Myelofibrosis (MF) is a rare hematopoietic stem cell disorder. Allogeneic hematopoietic cell transplantation (HCT) is a potential curative therapy for advanced MF, but MF patients have delayed engraftment compared to AML patients, leading to complications. This study investigated engraftment dynamics in MF patients and found that delayed neutrophil and platelet engraftment in MF is related to both host and treatment-related factors.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Jean-Baptiste Bossard, Jean-Baptiste Beuscart, Marie Robin, Mohamad Mohty, Fiorenza Barraco, Patrice Chevallier, Tony Marchand, Marie-Therese Rubio, Amandine Charbonnier, Didier Blaise, Jacques-Olivier Bay, Carmen Botella-Garcia, Gandhi Damaj, Florence Beckerich, Patrice Ceballos, Thomas Cluzeau, Jerome Cornillon, Mathieu Meunier, Corentin Orvain, Alain Duhamel, Federico Garnier, Jean-Jacques Kiladjian, Ibrahim Yakoub-Agha
Summary: A comprehensive retrospective study conducted using data from the French bone marrow transplantation registry revealed that pretransplant splenectomy does not preclude subsequent allogeneic hematopoietic cell transplantation in patients with myelofibrosis.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Xiangzong Zeng, Li Xuan, Zhiping Fan, Yu Zhang, Ke Zhao, Ya Zhou, Jun Xu, Qifa Liu, Min Dai
Summary: Patients with MF-2/3 have more complex karyotypes and lower ORR of cytoreduction in MDS. Among patients without allo-HSCT, patients with MF-2/3 have a worse prognosis than those with MF-0/1. However, the adverse impact of MF on prognosis may be overcome by allo-HSCT.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2021)
Article
Hematology
Desiree Kunadt, Sylvia Herold, David Poitz, Lisa Wagenfuhr, Theresa Kretschmann, Katja Sockel, Leo Ruhnke, Stefan Bruckner, Ulrich Sommer, Frieder Meier, Christoph Rollig, Malte von Bonin, Christian Thiede, Johannes Schetelig, Martin Bornhauser, Friedrich Stolzel
Summary: Although extramedullary manifestations are common in patients with acute myeloid leukemia, there are currently no established imaging or molecular strategies for diagnosing them. However, detecting extramedullary disease is crucial for making therapeutic decisions, as it is associated with aggressive and resistant disease. Mutational profiling may also help guide treatment strategies. This case highlights the importance of continuous molecular profiling of extramedullary disease and the use of PET imaging to detect residual disease and monitor treatment response.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2022)
Article
Immunology
Alessandro Marins-Dos-Santos, Jackline de Paula Ayres-Silva, Dina Antunes, Carlos Jose de Carvalho Moreira, Marcelo Pelajo-Machado, David Alfaro, Agustin G. Zapata, Adriana Cesar Bonomo, Wilson Savino, Juliana de Meis, Desio Aurelio Farias-de-Oliveira
Summary: This study demonstrates that Trypanosoma cruzi causes high tissue parasitism during the acute phase of Chagas disease. In mice with acute oral infection, the bone marrow cells are highly parasitized, particularly in the perivascular, intravascular, and near bone regions. The infection leads to a decrease in hematopoietic cells in the bone marrow, except for an increase in hematopoietic stem and progenitor cells. The study also suggests that the spleen may play a role in emergency hematopoiesis during acute T. cruzi infection. Overall, this research provides important insights into the impact of T. cruzi infection on the hematopoietic system.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Cell Biology
Alborz Karimzadeh, Erika S. Varady, Vanessa M. Scarfone, Connie Chao, Karin Grathwohl, Pauline U. Nguyen, Yasamine Ghorbanian, Irving L. Weissman, Thomas Serwold, Matthew A. Inlay
Summary: Hematopoietic stem cells (HSCs) are characterized by their self-renewal, multipotency, and bone marrow engraftment abilities. Pre-HSCs, intermediate precursors of HSCs thought to arise from hemogenic endothelium, lack bone marrow engraftability. CD11a has been identified as a critical marker for the identification and enrichment of pre-HSCs, and a proposed pre-HSC population named 11a- eKLS has been established in mouse embryos. Signals from the neonatal liver are suggested to mature pre-HSCs into bone marrow-engraftable HSCs.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
